natgillin/translations-raw huggingface dataset:
For more information, see ‘Blood clots in a vein 
Za dodatne informacije glejte »Krvni strdki v veni
This increase is most likely attributable to age-related changes in hepatic function. 
To zvečanje je najverjetneje mogoče pripisati starostnim spremembam v delovanju jeter.
The pharmacokinetics of a 20 mg single dose of BZA were evaluated in a study in 26 healthy postmenopausal women. 
Farmakokinetiko enkratnega 20 mg odmerka BZA so ocenili v študiji pri 26 zdravih ženskah v postmenopavzi.
The number of extra cases of stroke due to use of HRT will increase with age. 
Število dodatnih primerov možganske kapi zaradi uporabe HNZ se veča s starostjo.
BZA is highly bound (98% - 99%) to plasma proteins in vitro, but does not bind to sex hormone binding globulin (SHBG). 
BZA se in vitro v veliki meri (98 %-99 %) veže na beljakovine v plazmi, vendar se ne veže na globulin, ki veže spolne hormone (SHBG).
T3 resin uptake is decreased, reflecting the elevated TBG. 
Vezava T3 na smolo je zmanjšana, kar odraža zvečanje TBG.
What DUAVIVE is and what it is used for 
Kaj je zdravilo DUAVIVE in za kaj ga uporabljamo
Before initiating or reinstituting treatment with CE/BZA, a complete personal and family medical history should be taken. 
Pred začetkom prvega ali ponovnega zdravljenja s CE/BZA je treba raziskati celotno osebno in družinsko anamnezo.
Stop taking DUAVIVE and see a doctor immediately if you get any of the following serious side effects: 
Prenehajte jemati zdravilo DUAVIVE in nemudoma obiščite zdravnika, če opazite kateregakoli izmed spodaj navedenih resnih neželenih učinkov:
Coronary artery disease (CAD) 
Koronarna arterijska bolezen (KAB)
Women should be told to contact their doctors immediately when they are aware of a potential thromboembolic symptom (e.g., painful swelling of a leg, sudden pain in the chest, dyspnoea). 
Ženske je treba opozoriti, naj nemudoma obiščejo svojega zdravnika, če se pojavijo morebitni simptomi trombembolije (npr. boleče otekanje noge, nenadna bolečina v prsnem košu, dispneja).
The most commonly reported adverse reaction is abdominal pain, occurring in more than 10% of patients in clinical trials. 
Neželeni učinek, o katerem so najpogosteje poročali, je bila bolečina v trebuhu, ki se je med kliničnimi preskušanji pojavila pri več kot 10 % bolnic.
The expiry date refers to the last date of that month. 
Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Pharmacotherapeutic group: Sex hormones and modulators of the genital system; estrogens, combinations with other drugs; ATC code: G03CC07 
Farmakoterapevtska skupina: spolni hormoni in zdravila za uravnavanje delovanja spolovil; estrogeni v kombinaciji z drugimi učinkovinami; oznaka ATC: G03CC07.
This can cause symptoms such as hot face, neck and chest ("hot flushes"). 
To lahko povzroči simptome, kot je občutek vročine v obrazu, vratu in prsih (»vročinski oblivi«).
This medicine is for use only by postmenopausal women. 
To zdravilo je namenjeno uporabi samo pri ženskah po menopavzi.
CE/BZA has not been studied in women with baseline triglyceride levels >300 mg/dL (>3.4 mmol/L). 
Kombinacije CE/BZA pri ženskah z izhodiščnimi vrednostmi trigliceridov > 300 mg/dl (> 3,4 mmol/l) niso raziskovali.
Talk to your doctor before taking this medicine if you have ever had any of the following problems, as these may return or become worse during treatment with DUAVIVE. 
Pred začetkom jemanja tega zdravila se posvetujte z zdravnikom, če ste kadarkoli imeli ali imate katerokoli izmed naštetih bolezni, saj se te med zdravljenjem z zdravilom DUAVIVE lahko ponovijo ali poslabšajo.
Women already on chronic anticoagulant treatment require careful consideration of the benefit risk of use of hormone therapy. 
Pri ženskah, ki se že kronično zdravijo z antikoagulansi, je treba skrbno pretehtati razmerje koristi in tveganja hormonskega zdravljenja.
• Worsening of porphyria, a rare blood disorder which is passed down in families (inherited). 
• poslabšanje porfirije, redke bolezni krvi, ki se prenaša v družini (je dedna).
• An effect on the way in which your blood sugar (glucose) levels are controlled including increased glucose levels in the blood 
• vpliv na način, na katerega telo nadzira ravni sladkorja v krvi (glukozo), vključno z zvišanimi ravnmi glukoze v krvi;
Depending on the duration of oestrogen-only use and oestrogen dose, the increase in risk of endometrial cancer in epidemiology studies varied from 5 to 55 extra cases diagnosed in every 1,000 women between the ages of 50 and 65 years. 
Glede na trajanje zdravljenja samo z estrogenom in odmerke estrogena je znašalo zvečanje tveganja za raka endometrija v epidemioloških študijah med 5 in 55 dodatnih diagnosticiranih primerov na vsakih 1.000 žensk, starih od 50 do 65 let.
Before you start taking this medicine, your doctor will ask you about your own and your family's medical history. 
Preden začnete uporabljati to zdravilo, vas bo zdravnik vprašal o vaši osebni in družinski anamnezi (pretekle bolezni in zdravstvena stanja vas in vaših družinskih članov).
Breast cancer risk associated with the use of oestrogens alone is represented by several studies. 
Tveganje za raka dojke, povezano z uporabo samo estrogena, so predstavili v več študijah.
If any of the above conditions appear for the first time while taking this medicine, stop taking it at once and consult your doctor immediately. 
Če se katerakoli izmed zgoraj navedenih bolezni prvič pojavi med tem, ko jemljete to zdravilo, ga nemudoma prenehajte jemati in se posvetujte z zdravnikom.
In women with no personal history of VTE but with a first-degree relative with a history of thrombosis at young age, screening may be offered after careful counselling regarding its limitations (only a proportion of thrombophilic defects are identified by screening). 
Ženskam, ki nimajo VTE v osebni anamnezi, vendar imajo sorodnika v prvem kolenu z anamnezo tromboze v mladosti, se lahko predlaga presejalni pregled po temeljitem svetovanju o omejitvah takšnega testiranja (pri presejalnih pregledih se odkrije le del trombofiličnih okvar).
This medicine contains 0.0088 mg sorbitol in each tablet. 
To zdravilo vsebuje 0,0088 mg sorbitola na tableto.
In postmenopausal women, a significant proportion of the circulating oestrogens exists as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active oestrogens. 
Pri ženskah v postmenopavzi velik delež estrogenov v obtoku obstaja v obliki sulfatnih konjugatov, zlasti estronsulfata, ki deluje kot skladišče za tvorbo aktivnejših estrogenov.
For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used (see section 4.4). 
Za začetek in nadaljevanje zdravljenja simptomov postmenopavze je treba uporabiti najmanjši učinkoviti odmerek, trajanje uporabe pa mora biti čim krajše (glejte poglavje 4.4).
Pharmacokinetic studies for CE/BZA were conducted in healthy postmenopausal women who were naturally postmenopausal or who had undergone bilateral oophorectomy. 
Farmakokinetične študije kombinacije CE/BZA so izvedli pri zdravih ženskah v postmenopavzi, ki so bile naravno v postmenopavzi ali pa so imele bilateralno ooforektomijo.
The following data are based on the findings in studies with bazedoxifene. 
Podatki v nadaljevanju temeljijo na ugotovitvah študij z bazedoksifenom.
Other medicines and DUAVIVE 
Druga zdravila in zdravilo DUAVIVE
These substitute for the loss of oestrogen production in menopausal women, and alleviate menopausal symptoms. 
Ti nadomeščajo nezmožnost tvorbe estrogena pri ženskah v menopavzi in lajšajo menopavzalne simptome.
Adverse reactions were categorised as very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare ( 1/10,000 to < 1/1,000), very rare (< 1/10,000) or not known (cannot be estimated from available data). 
Neželeni učinki so bili razvrščeni kot zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) ali neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Medical examination/follow-up 
Zdravstveni pregled/kontrolni pregled
Venous thromboembolism (VTE) 
Venska trombembolija (VTE)
What you need to know before you take DUAVIVE 
Kaj morate vedeti, preden boste vzeli zdravilo DUAVIVE
The distribution of exogenous oestrogens is similar to that of endogenous oestrogens. 
Porazdelitev eksogenih estrogenov je podobna porazdelitvi endogenih estrogenov.
- Acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal. 
- Akutna bolezen jeter ali bolezen jeter v anamnezi, dokler se vrednosti testov funkcije jeter ne vrnejo na normalne.
• regularly check your breasts for any changes such as dimpling of the skin, changes in the nipple, or any lumps you can see or feel. 
• si redno pregledujete dojke in ste pozorni na vse spremembe, kot so nastanek jamic na koži, spremembe na bradavicah ali kakršnekoli zatrdline, ki jih lahko vidite ali otipate.
The following data are based on the findings in studies with BZA. 
Podatki v nadaljevanju temeljijo na ugotovitvah študij z BZA.
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
There are no data from the use of CE/BZA in pregnant women. 
Podatkov o uporabi CE/BZA pri nosečnicah ni.
The risk of ovarian cancer varies with age. 
Tveganje za raka jajčnikov se spreminja s starostjo.
Swallow tablet whole. 
Tableto pogoltnite celo.
CE components, 17β-estradiol, estrone, and estriol are excreted in the urine, along with glucuronide and sulfate conjugates. 
Komponente CE, 17β-estradiol, estron in estriol, se izločijo z urinom, skupaj z glukuronidom in sulfatnimi konjugati.
There were no significant pharmacokinetic interactions between bazedoxifene and the following medicinal products: ibuprofen, atorvastatin and azithromycin or an antacid containing aluminium and magnesium hydroxide. 
Med bazedoksifenom in naslednjimi zdravili ni bilo pomembnih farmakokinetičnih interakcij: ibuprofen, atorvastatin, azitromicin ali antacid, ki vsebuje aluminijev in magnezijev hidroksid.
Patients treated with CE/BZA should be monitored carefully for signs of development of gallbladder disease. 
Bolnice, ki se zdravijo s CE/BZA, je treba skrbno spremljati glede znakov pojava bolezni žolčnika.
Red Iron oxide (E172) 
Črnilo črni železov oksid (E172)
Among these, 1,585 women were treated with CE 0.45 mg/BZA 20 mg and 1,241 received placebo. 
Med njimi je 1.585 žensk prejemalo 0,45 mg CE /20 mg BZA, 1.241 žensk pa je prejemalo placebo.
BZA is eliminated with a half-life of approximately 30 hours. 
Razpolovna doba izločanja BZA je približno 30 ur.
Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1 antitrypsin, ceruloplasmin). 
Koncentracije drugih beljakovin v plazmi se lahko zvečajo (angiotenzinogen/substrat renina, alfa-1-antitripsin, ceruloplazmin).
Heart disease (heart attack) 
Bolezen srca (srčna kap)
Conditions which need supervision 
Bolezenska stanja, pri katerih je potreben nadzor
If prolonged immobilisation is to follow elective surgery temporarily stopping CE/BZA 4 to 6 weeks earlier is recommended. 
Če elektivnemu kirurškemu posegu sledi daljša imobilizacija, je priporočljivo zdravljenje s CE/BZA začasno prekiniti 4 do 6 tednov pred posegom.
The bazedoxifene component of this medicine has been reported to cause problems with eyesight such as blurred vision. 
Poročali so, da bazedoksifenska komponenta tega zdravila povzroča težave z vidom, npr. zamegljen vid.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake Uporabno do.
DUAVIVE is indicated for the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. 
Zdravilo DUAVIVE je indicirano za zdravljenje simptomov pomanjkanja estrogena pri ženskah v postmenopavzi z maternico (vsaj 12 mesecev od zadnje menstruacije), pri katerih zdravljenje s progestini ni primerno.
On average, compared to women 51 to 64 years of age (n=8), women 65 to 74 years of age (n=8) showed a 1.5-fold increase in AUC, and women 75 years of age (n=8) showed a 2.6-fold increase in AUC. 
V primerjavi z ženskami, starimi od 51 do 64 let (n = 8), so pri ženskah, starih od 65 do 74 let (n = 8), opazili povprečno 1,5-kratno zvečanje vrednosti AUC, pri ženskah, starih 75 let (n = 8), pa 2,6-kratno zvečanje vrednosti AUC.
For women with a history of cholestatic jaundice associated with past oestrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, CE/BZA should be discontinued. 
Pri ženskah s holestatskim ikterusom, povezanim s preteklo uporabo estrogenov ali z nosečnostjo, je potrebna previdnost, pri ponovitvi bolezni pa je treba zdravljenje s CE/BZA prekiniti.
*WHI study in women with no uterus, which did not show an increase in risk of breast cancer 
* Študija WHI pri ženskah brez maternice, pri katerih niso ugotovili zvečanega tveganja za raka dojke.
These may be signs of a liver disease 
To sta lahko znaka bolezni jeter;
• Changes in mood 
• spremembe razpoloženja;
• Cervical erosion found on medical examination 
• erozija materničnega vratu, ugotovljena pri zdravniškem pregledu;
If you forget to take DUAVIVE 
Če ste pozabili vzeti zdravilo DUAVIVE
• high blood pressure 
• visok krvni tlak;
DUAVIVE is a medicine that contains two active substances called conjugated oestrogens and bazedoxifene. 
DUAVIVE je zdravilo, ki vsebuje dve učinkovini, imenovani konjugirani estrogeni in bazedoksifen.
Of the total number of women in phase 3 clinical trials who received CE/BZA 20 mg, 2.4% (n=77) were aged ≥65 years. 
Od skupnega števila žensk v kliničnih preskušanjih 3. faze, ki so prejemale CE/BZA, jih je bilo 2,4 % (n = 77) starih ≥ 65 let.
If you have any unexpected vaginal bleeding, you must contact your doctor as soon as possible. 
Če se vam pojavijo nepričakovane krvavitve iz nožnice, morate čimprej obvestiti zdravnika.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product. 
Bolnice z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze, intoleranco za fruktozo, malabsorpcijo glukoze/galaktoze ali pomanjkanjem saharaze-izomaltaze ne smejo jemati tega zdravila.
This medicine contains conjugated oestrogens and bazedoxifene and is used to treat women with a uterus (womb). 
To zdravilo vsebuje konjugirane estrogene in bazedoksifen, uporablja pa se za zdravljenje žensk, ki imajo maternico.
If you take more DUAVIVE than you should 
Če ste vzeli večji odmerek zdravila DUAVIVE, kot bi smeli
Relief of oestrogen-deficiency symptoms and bleeding patterns 
Lajšanje simptomov pomanjkanja estrogena in vzorci krvavitve
Adverse reactions were categorised as very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100) or rare ( 1/10,000 to < 1/1,000). 
Neželeni učinki so bili razvrščeni kot zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do < 1/100) ali redki ( 1/10.000 do
If such symptoms occur, patients should avoid driving or use of machines that requires accurate visual perception until symptoms have resolved, or until they have received medical advice that it is safe to do so. 
Če se pojavijo taki simptomi, se morajo bolnice izogibati vožnji ali upravljanju strojev, ki zahtevajo natančno vidno zaznavo, dokler simptomi ne izzvenijo ali dokler jim zdravnik ne svetuje, da so te dejavnosti varne.
It may harm them, 
ki je imela raka dojke);
CE/BZA has a minor influence on the ability to drive and use machines. 
Kombinacija CE/BZA ima blag vpliv na sposobnost vožnje in upravljanja strojev.
- Jaundice or deterioration in liver function - Significant increase in blood pressure -New onset of migraine-type headache 
- zlatenica ali poslabšanje delovanja jeter; - pomembno zvišanje krvnega tlaka; - nov napad migrenskega glavobola.
In clinical trials with bazedoxifene monotherapy, somnolence was reported as an adverse reaction, and patients should be advised on the potential effect on driving and using machines. 
V kliničnih preskušanjih z monoterapijo z bazedoksifenom so poročali o zaspanosti kot neželenem učinku, zato je treba bolnice opozoriti na možne učinke na sposobnost vožnje in upravljanja strojev.
Risk ratio & 95% CI 
Razmerje tveganja in 95 % IZ
Epidemiological evidence from a large meta-analysis suggests a slightly increased risk in women taking oestrogen-only Hormone Replacement Therapy (HRT), which becomes apparent within 5 years of use and diminishes over time after stopping. 
Epidemiološki podatki iz obširne metaanalize kažejo rahlo zvečano tveganje pri ženskah, ki uporabljajo samo estrogensko hormonsko nadomestno zdravljenje (HNZ), kar postane očitno po 5 letih uporabe in se po prenehanju sčasoma počasi zmanjšuje.
The following side effects have been observed when either conjugated oestrogens and/or bazedoxifene (the active ingredients in this medicine) has been used alone and may occur also with this medicine: 
Naslednje neželene učinke so opazili pri jemanju konjugiranih estrogenov in/ali bazedoksifena (učinkovin v tem zdravilu) kot samostojnih zdravil, lahko pa se pojavijo tudi pri tem zdravilu:
The additional risk of ischaemic stroke over five years of use was assessed in the largest randomised trial in women without a uterus (WHI) from 50-59 years of age. 
Dodatno tveganje za ishemično možgansko kap v petih letih uporabe so ocenili v največjem randomiziranem preskušanju pri ženskah brez maternice (WHI), starih od 50 do 59 let.
Do not store above 25C. 
Shranjujte pri temperaturi do 25 C.
Uncommon: may affect 1 in 100 people • If you begin to get migraine-like headaches, or severe headaches 
Občasni: pojavijo se lahko pri 1 od 100 bolnic • če se pojavijo glavoboli, podobni migreni, ali hudi glavoboli.
• increased risk of developing blood clots [see “Blood clots in a vein (thrombosis)﻿ 
• zvečano tveganje za razvoj krvnih strdkov (glejte »Krvni strdki v veni (tromboza)«);
• if any of your close relatives has ever had a blood clot in the leg, lung or another organ 
• če je kdorkoli v ožji družini imel krvni strdek v nogi, pljučih ali drugem organu;
Risk ratio 
Razmerje tveganja
• A worsening of asthma 
• poslabšanje astme;
Generally recognised risk factors for VTE include, use of oestrogens, older age, major surgery, prolonged immobilisation, obesity (BMI > 30 kg/m2), pregnancy/postpartum period, systemic lupus erythematosus (SLE), and cancer. 
Splošno znani dejavniki tveganja za VTE vključujejo uporabo estrogenov, starost, večji kirurški poseg, dolgotrajno imobilizacijo, debelost (ITM > 30 kg/m2), nosečnost/poporodno obdobje, sistemski eritematozni lupus (SLE) in raka.
If so, you should see your doctor more often for check-ups: 
Če to za vas drži, morate zdravnika obiskovati pogosteje:
Therapy should be discontinued in case a contraindication is discovered (e.g., venous thromboembolism, stroke, and pregnancy) and in the following situations: 
Zdravljenje je treba prekiniti, če se odkrije kontraindikacija (npr. venska trombembolija, možganska kap in nosečnost) in v naslednjih primerih:
- Untreated endometrial hyperplasia. 
- Nezdravljena hiperplazija endometrija.
- Oestrogens may cause fluid retention, and therefore patients with cardiac or renal dysfunction should be carefully monitored when being treated with CE/BZA. 
- Estrogeni lahko povzročijo zastajanje tekočine v telesu, zato je treba bolnice z motenim delovanjem srca ali ledvic med zdravljenjem s CE/BZA skrbno spremljati.
Relief of symptoms occurring after menopause 
Lajšanje simptomov, ki se pojavijo po menopavzi
• Blood clot in a vein at the back of the eye (retinal vein) which may lead to loss of vision 
• krvni strdek v veni na zadnjem delu očesa (mrežnična vena), ki lahko povzroči izgubo vida;
• Erythema multiforme: symptoms may include skin rash with pink-red blotches especially on palms of hands or soles of feet which may blister. 
• multiformni eritem: simptomi lahko vključujejo izpuščaj na koži z rožnato-rdečimi madeži, zlasti na dlaneh ali podplatih, kjer se lahko pojavijo tudi mehurji.
• Changes in your interest in sex (increased or decreased libido) 
• spremembe v zanimanju za spolnost (zvečan ali zmanjšan libido);
The disposition of a single 20 mg dose of bazedoxifene was compared in women with hepatic impairment (Child-Pugh Class A [n=6], B [n=6], and C [n=6]) and subjects with normal hepatic function (n=18). 
Farmakokinetiko enkratnega 20 mg odmerka bazedoksifena so primerjali pri ženskah z okvaro jeter (razred A [n = 6], B [n = 6] in C [n = 6] po Child-Pughovi lestvici) in preiskovankah z normalnim delovanjem jeter (n = 18).
- Women with pre-existing hypertriglyceridaemia should be followed closely during treatment with oestrogens, since rare cases of large increases of plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition. 
- Ženske z obstoječo hipertrigliceridemijo je treba med zdravljenjem z estrogeni skrbno opazovati, ker so v redkih primerih pri zdravljenju bolnic v takem stanju z estrogenom poročali o velikem zvečanju trigliceridov v plazmi, ki je vodilo v pankreatitis.
* Taken from baseline incidence rates in developed countries Overall risk ratio. 
* Na podlagi izhodiščne incidence v razvitih državah.
Bazedoxifene belongs to a group of non-hormonal medicines called selective estrogen receptor modulators (SERMs). 
Bazedoksifen spada v skupino nehormonskih zdravil, imenovano selektivni modulatorji estrogenskega receptorja (SERM).
In clinical trials of up to 2 years duration in postmenopausal women with CE/BZA, cases of VTE have been reported (see section 4.8). 
V kliničnih preskušanjih pri ženskah v postmenopavzi s CE/BZA, ki so trajala do 2 leti, so poročali o primerih VTE (glejte poglavje 4.8).
Million women study (Estradiol only arm) - estimated additional risk of breast cancer after 5 years use 
Študija Million Women Study (skupina, ki je prejemala samo estradiol) - ocenjeno dodatno tveganje za raka dojke po 5 letih uporabe
• Medicines for tuberculosis (such as rifampicin, rifabutin); 
• zdravila za zdravljenje tuberkuloze (kot sta rifampicin, rifabutin);
Blood clots can be serious, and if one travels to the lungs, it can cause chest pain, breathlessness, collapse or even death. 
Krvni strdki so lahko resni, ob prehodu v pljuča pa lahko povzročijo bolečine v prsnem košu, zasoplost, kolaps ali celo smrt.
Results from a clinical drug-drug interaction study conducted with CE/BZA and from interaction studies with CE or bazedoxifene monotherapy are summarised below. 
Rezultati klinične študije medsebojnega delovanja, ki so jo izvedli s CE/BZA, in študij medsebojnega delovanja, ki so jih izvedli s CE ali monoterapijo z bazedoksifenom, so povzeti spodaj.
Physical (including pelvic and breast) examination should be guided by this and by the contraindications and precautions for use. 
Telesni pregled (vključno z medeničnim predelom in dojkami) je treba opraviti glede na anamnezo, kontraindikacije in previdnostne ukrepe za uporabo.
On average, women with hepatic impairment showed a 4.3-fold increase in AUC compared with controls. 
Pri ženskah z okvaro jeter je bila vrednost AUC povprečno 4,3-krat večja kot pri ženskah v kontrolni skupini.